http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3501539-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a927f1f067199696bd0d205a9a123d8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb39996ac1b18f8226c542a106050bb1 |
| publicationDate | 2019-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3501539-A1 |
| titleOfInvention | Application of anti-pl2l60 protein antibody in preparing anti-tumor drug and method for treating tumors |
| abstract | The disclosure relates to the field of medical technology, and provides use of an agent for inhibiting the ectopic expression of a PIWIL2 gene and a protein antibody against the ectopic expression of the PIWIL2 gene in preparation of an anti-tumor drug. The disclosure also provides an anti-tumor pharmaceutical composition and a method for treating a tumor. It has been experimentally proved that, treating human or mouse tumor cells with KAO3 upon inoculation can effectively inhibit the tumorigenesis in a mouse. Furthermore, injecting KAO3 into established lymphoma, breast cancer, lung cancer and cervical cancer can significantly inhibit tumor growth and prolong the survival of a tumor-bearing mouse. The inhibitory effect of KAO3 is associated with KAO3-specific antigens expressed on the surface of a tumor cell. KAO3 induces apoptosis of the tumor cell by blocking the cell cycle in a G2/M phase, inhibiting DNA synthesis and activating a complement. Therefore, the anti-PL2L60 mAb (KAO3) is a potential therapeutic candidate drug for treating a cancer. |
| priorityDate | 2017-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 205.